KRAS and non-small cell lung carcinoma: In tumors from patients with NSCLC who received adjuvant chemotherapy, a prognostic impact was not observed with PD-L1 expression at TC ≥25%/IC ≥25%/IC ≥1% cutoffs, or with KRAS mutations.